Waltham, MA-based EyeGate Pharmaceuticals announced yesterday that it added $5.9 million to its Series D funding round, bringing the financing’s total to $28.5 million to date. The biotech works on delivering drugs to the eye, and said the new money will go toward EGP-437, its dexamethasone-derived corticosteroid treatment for dry eye syndrome. In September Eyegate inked a partnership deal with Worcester, MA-based RXi Pharmaceuticals (NASDAQ: [[ticker:RXII]]) to deliver RNA interference therapeutics to the eye for the treatment of retinal disorders.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
